ESLAW

Estrella Immunopharma, Inc. Warrant

Healthcare — BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Valhalla Score —

—

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

📊 Key Statistics

Market Cap—

P/E Ratio—

EPS (TTM)—

EPS YoY—

Revenue YoY—

Float—

Short Float %—

Inst. Ownership—

Sector RS—

📈 Fundamentals

ROE—

ROIC—

ROA—

Current Ratio—

Debt/Equity—

Gross Margin—

Net Margin—

Dividend Yield—

Next Earnings—

⚡ Options Summary

Call OI—

Put OI—

P/C Ratio (OI)—

Gamma Environment—

Max Pain—

Call Wall—

Put Wall—

🎯 Analyst Estimates

Consensus Target—

High Target—

Low Target—

Analysts—

Upside/Downside—

📋 Quarterly Financials

Period	Revenue	Rev YoY	EPS	EPS YoY	Gross Margin

Start Free Trial See full options flow, dark pool data & more

🔥 Recent Options Flow

Type	Strike	Exp	Size	Premium	Time

Start Free Trial Institutional trades, dark pool vs lit exchange

🏛️ Institutional Trades

Type	Price	Size	Value	Venue	Time

Start Free Trial Full insider & congressional trade history

👤 Insider Trades

Name	Type	Shares	Price	Date

Start Free Trial Top institutional holders & ownership data

🏦 Top Institutional Holders

Institution	Shares	Value	% of Class